Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products >  > 

Lansoprazole

Related Products

Hot Products

Basic Information Post buying leads Suppliers
Name

Lansoprazole

EINECS
CAS No. 103577-45-3 Density 1.5 g/cm3
Solubility Melting Point 178-182 °C
Formula C16H14F3N3O2S Boiling Point 555.8 °C at 760 mmHg
Molecular Weight 369.36 Flash Point 289.9 °C
Transport Information Appearance white crystalline powder
Safety 26-36 Risk Codes 36/37/38
Molecular Structure Molecular Structure of 103577-45-3 (Lansoprazole) Hazard Symbols IrritantXi
Synonyms

Amarin;Promp;Monolitum;Lanz;Prevacid (TN);Ulpax;Lansoprazolum [INN-Latin];Takepron;Blason;2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole;Ilsatec;A 65006;Bamalite;Prevacid SoluTab;Lansopep;2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole;Limpidex;Pro Ulco;Zoton;Lanproton;Lansoprazol [INN-Spanish];Lansoprazole [USAN:BAN:INN];Ogastro;1H-Benzimidazole, 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-;AG 1749;Dakar;1H-Benzimidazole,2-[[[3-methyl-4-(2,2,2- trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-;Agopton;2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzoimidazole;Prosogan;

 

Lansoprazole Specification

The Lansoprazole with CAS registry number of 103577-45-3 is also known as 1H-Benzimidazole, 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-. The IUPAC name is 2-[[3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole. It belongs to product categories of Active Pharmaceutical Ingredients; Intermediates & Fine Chemicals; Pharmaceuticals; Sulfur & Selenium Compounds; Ion Pump Inhibitors; Monovalent Ion Channels; Voltage-gated Ion Channels; ATPase; Pharmaceutical Intermediates. In addition, the formula is C16H14F3N3O2S and the molecular weight is 369.36. This chemical is a white crystalline powder and should be sealed in cool place without light. What's more, it can be used for the treatment of duodenal ulcer embolism and it is a proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid.

Physical properties about Lansoprazole are: (1)ACD/LogP: 2.76; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): 2.75; (4)ACD/LogD (pH 7.4): 2.76; (5)ACD/BCF (pH 5.5): 72.3; (6)ACD/BCF (pH 7.4): 72.89; (7)ACD/KOC (pH 5.5): 740.79; (8)ACD/KOC (pH 7.4): 746.86; (9)#H bond acceptors: 5; (10)#H bond donors: 1; (11)#Freely Rotating Bonds: 5; (12)Index of Refraction: 1.635; (13)Molar Refractivity: 88.03 cm3; (14)Molar Volume: 245.8 cm3; (15)Surface Tension: 68.9 dyne/cm; (16)Density: 1.5 g/cm3; (17)Flash Point: 289.9 °C; (18)Enthalpy of Vaporization: 83.72 kJ/mol; (19)Boiling Point: 555.8 °C at 760 mmHg; (20)Vapour Pressure: 2.16E-12 mmHg at 25 °C.

Preparation of Lansoprazole: it is prepared by reaction of 2-[3-methyl-4-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethylsulfanyl]-1H-benzoimidazole. The reaction needs reagent m-chloroperbenzoic acid and solvent CHCl3 with other condition of ice-cooling. The yield is about 45%.

Lansoprazole is prepared by reaction of 2-[3-methyl-4-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethylsulfanyl]-1H-benzoimidazole.

When you are using this chemical, please be cautious about it. As a chemical, it is irritating to eyes, respiratory system and skin. During using it, wear suitable protective clothing. If contact with eyes accidently, rinse immediately with plenty of water and seek medical advice.

You can still convert the following datas into molecular structure:
1. Canonical SMILES: CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
2. InChI: InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,
18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)
3. InChIKey: MJIHNNLFOKEZEW-UHFFFAOYSA-N

The toxicity data is as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LD oral > 2gm/kg (2000mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 35, Pg. 387, 1993.
mouse LD50 intraperitoneal > 5gm/kg (5000mg/kg) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)

BEHAVIORAL: MUSCLE WEAKNESS

KIDNEY, URETER, AND BLADDER: OTHER CHANGES
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 18(Suppl,
mouse LD50 oral > 5gm/kg (5000mg/kg) KIDNEY, URETER, AND BLADDER: OTHER CHANGES Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 18(Suppl,
mouse LD50 subcutaneous > 5gm/kg (5000mg/kg)   Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 18(Suppl,
mouse LDLo intravenous 75mg/kg (75mg/kg) SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 24, Pg. 905, 1996.
rat LD50 intraperitoneal 5gm/kg (5000mg/kg) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)

BEHAVIORAL: MUSCLE WEAKNESS

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 18(Suppl,
rat LD50 oral > 5gm/kg (5000mg/kg)   Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 18(Suppl,
rat LD50 subcutaneous > 5gm/kg (5000mg/kg)   Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 18(Suppl,
rat LDLo intravenous 58mg/kg (58mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: ATAXIA

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 24, Pg. 905, 1996.

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields